ctDNA Can Be Used For Patient Selection and Enrichment, But Not As Early Efficacy Endpoint, US FDA Says

More data are required to establish circulating tumor DNA, a blood biomarker, as reasonably likely to predict benefit on long-term outcomes in early-stage, solid tumor trials, agency says in new draft guidance.

Selected person
Circulating tumor DNA can be used to select patients for clinical trials. • Source: Shutterstock

Circulating tumor DNA (ctDNA) can be used as a biomarker in early-stage solid tumor clinical trials for purposes of patient selection, patient enrichment and as a measure of response. However, further data are needed to support use as an endpoint reasonably likely to predict long-term outcome, the US Food and Drug Administration said.

In a new draft guidance, the agency provides recommendations on uses of ctDNA as a biomarker in the early-stage...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Clinical Trials

Canada Cuts Red Tape With Single Ethics Review For Trials

A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.

Diversity Action Plans: What To Submit And When

 
• By 

With the deadline for comments on the US FDA’s draft guidance less than a month away, the Pink Sheet offers an infographic outlining what the agency is expecting in diversity action plans and when that might be implemented.

India Tightens Oversight Of CROs With Mandatory Registration

 
• By 

Contract research organizations (CROs) in India must gear up to comply with new registration requirements coming into effect in April 2025 that aim to enhance the quality and integrity of clinical trials, as well as of any bioavailability and bioequivalence studies conducted by them.

UK Expedites Cost Negotiations For Companies Conducting ATMP & Early Phase Trials

 

Companies dealing with commercial costings or contracts with the National Health Service for early phase clinical trials or trials of advanced therapy medicinal products should soon be able to conclude their negotiations more quickly.

More from R&D

India Tightens Oversight Of CROs With Mandatory Registration

 
• By 

Contract research organizations (CROs) in India must gear up to comply with new registration requirements coming into effect in April 2025 that aim to enhance the quality and integrity of clinical trials, as well as of any bioavailability and bioequivalence studies conducted by them.

Clinical Trial Diversity Action Plans Need Timely FDA Feedback, Groups Say

 
• By 

The agency also should explain the potential consequences for sponsors if enrollment goals are not met, stakeholders say in comments on the DAP draft guidance. Some commenters urged the FDA to apply waiver criteria flexibly, especially for rare diseases.

How To Decarbonize Pharma R&D

 

As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.